Skip to main content

RT @RichardPAConway: Gurwith et al ABP-671 a URAT1 inhibitor effectively lowers serum urate @RheumNow #ACR22 Abstr#1822

Social Author Name
Richard Conway
Tweet Content
Gurwith et al ABP-671 a URAT1 inhibitor effectively lowers serum urate @RheumNow #ACR22 Abstr#1822 https://t.co/hXAQoVHrLH https://t.co/saVqu4kbnr

RT @ericdeinmd: L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nr

Social Author Name
Eric Dein
Tweet Content
L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure. AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%) @RheumNow https://t.co/G31PrfqtVu

RT @ericdeinmd: L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS P3b: SEC 150 mg v SEC 300 v

Social Author Name
Eric Dein
Tweet Content
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS P3b: SEC 150 mg v SEC 300 v SDZ-ADL Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance Hard to assess as overall, low rate of progression @RheumNow

RT @RichardPAConway: Lindegren et al. Dairy intake and RA risk in Sweden. Nested case-control. High regular milk intake

Social Author Name
Richard Conway
Tweet Content
Lindegren et al. Dairy intake and RA risk in Sweden. Nested case-control. High regular milk intake assoc increased risk (OR 1.90) High cheese assoc decresaed risk (OR 0.52) @RheumNow #ACR22 Abstr#1758 https://t.co/jUz3SJBf4Y https://t.co/ZykW3NjSrK

RT @Janetbirdope: A spicy result. say NO to turmeric in #rheumatoidarthritis Eat it on food, but don’t expect it to

Social Author Name
Janet Pope
Tweet Content
A spicy result. say NO to turmeric in #rheumatoidarthritis Eat it on food, but don’t expect it to help your joints. @RheumNow #ACR22 https://t.co/1mZBm3rYAA

RT @RichardPAConway: Utamawatin et al. DB-RCT of Triamcinolone 10mg vs 40mg for knee OA. No difference! Wonder if 10mg w

Social Author Name
Richard Conway
Tweet Content
Utamawatin et al. DB-RCT of Triamcinolone 10mg vs 40mg for knee OA. No difference! Wonder if 10mg would be better than saline? @RheumNow #ACR22 Abstr#1890 https://t.co/vcKze7mSf4 https://t.co/ErEkmUN0Wp

RT @Janetbirdope: Problem w antibodies to prevent #COVID19 infection in rheumatic Pts is that they are not as good in va

Social Author Name
Janet Pope
Tweet Content
Problem w antibodies to prevent #COVID19 infection in rheumatic Pts is that they are not as good in variants that are more prominent ex Omicron strains. But should we use in high risk Pts ex long rituximab users? I do in this group. @RheumNow #ACR22 https://t.co/A8soYbg9ZD

RT @RichardPAConway: Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher admin

Social Author Name
Richard Conway
Tweet Content
Baraliakos et al. AEs with SC vs IV infliximab. Relatively comparable safety profiles. Higher administration site reactions in SC. @RheumNow #ACR22 Abstr#1769 https://t.co/KnYlvifDlr https://t.co/VnKOYs86Xz

RT @DrCassySims: Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow

Social Author Name
Catherine Sims, MD
Tweet Content
Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬

RT @RichardPAConway: Lillegraven @SiriLillegraven ARCTIC REWIND. RA patients flare-free on half-dose csDMARD x 12 months

Social Author Name
Richard Conway
Tweet Content
Lillegraven @SiriLillegraven ARCTIC REWIND. RA patients flare-free on half-dose csDMARD x 12 months - randomised to continue or stop. Flare 38% vs 17% over 12 months. DAS remission 96% vs 90%. Absence radiograph prog 84% vs 69% @RheumNow #ACR22 Abstr#2013 https://t.co/uOwd8Io5wZ https://t.co/SKWPE7GBrx
Subscribe to
×